Nichi-Iko Pharmaceutical Co., Ltd. (Toyama, Japan; President and CEO: Yuichi Tamura, 'NichiIko') and Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director: Gyo Sagara; 'ONO') announced that the Companies have entered into the license agreement including patents, and technical collaboration on Opalmon (generic name: limaprost alfadex) Tablet 5 -microg, an oral Prostaglandin E1 analogue, manufactured and marketed by ONO in Japan.

Nichi-Iko will convert the formulation of 'Limaprost Alfadex tablets 5 -microg (Nichiiko)', currently manufactured and marketed by Nichi-Iko, to a formulation which has been improved for moisture resistance stability following the technology transfer based on patents owned by ONO. After receiving an approval for this improved formulation change, for a partial change in approved items of the manufacturing and marketing approval, Nichi-Iko will manufacture and market the improved formulation in bulk packaging standards through this technical collaboration.

Ono will continue to manufacture and market Opalmon Tablet 5 -microg.

Contact:

Tel: +81-(0)76-442-7026

(C) 2020 Electronic News Publishing, source ENP Newswire